Araz Marachelian, MD

Photo of Araz Marachelian, MD
Title(s)Assistant Professor of Clinical Pediatrics
SchoolKeck School of Medicine of Usc
AddressCHL Mail Stop 54
Off Campus
Los Angeles CA 90089
Phone+1 323 361 8573
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    1994Undergraduate Research Award National Science Foundation
    University of California, Berkeley1995Outstanding Service Award
    University of California, Berkeley1995High Distinction of Honors
    University of California, Irvine1999Outstanding Achievement in Pediatrics and Psychiatry
    AACR/ASCO2005Clinical Trial Training Workshop Award
    2009  - 2010Southern California Super Doctors
    Pasadena Magazine2013Top Doctor
    2014Southern California Super Doctors
    2014  - 2015NCI Cancer Clinical Investigator Team Leadership Award (CCITLA)

    Collapse Featured Content 
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors. JCO Oncol Pract. 2026 Jun 22; OP2501414. Migotsky M, Durazo-Arvizu R, Freyer DR, Robison N, Marachelian A, Orgel E. PMID: 42330418.
      View in: PubMed   Mentions:    Fields:    
    2. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195. Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. PMID: 41823156.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children's Oncology Group. Cancer. 2026 Jan 15; 132(2):e70165. Desai AV, Naranjo A, LaBarre B, Chen L, Goldsmith KC, Granger MP, States L, Green SG, Trunzo M, Fitzgerald W, DuBois SG, Bagatell R, Park JR, Marachelian A. PMID: 41527287; PMCID: PMC12796553.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2026 Jan 06; 32(1):127-134. Hazard FK, Toland AMS, Tan SY, Chiu B, Ikegaki N, Naranjo A, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Reshmi SC, Wagner E, Nuchtern J, Asgharzadeh S, Marachelian A, Maris JM, Bagatell R, Park JR, Irwin MS, Hogarty MD, Shimada H. PMID: 41143597; PMCID: PMC12596000.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025 08; 43(22):2490-2501. Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, Acharya PT, Pawel B, Erbe AK, Shahi A, Zaborek J, Kennedy E, Asgharzadeh S, Villablanca JG, Pinto N, Weiss BD, Mosse YP, Desai AV, Macy ME, Granger M, Vo KT, Sondel PM, Matthay KK, Park JR, Goldsmith KC. PMID: 40549985; PMCID: PMC12226806.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    6. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751. DuBois SG, Ogawa C, Moreno L, Mossé YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. PMID: 39932800.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    7. Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial. Br J Cancer. 2024 03; 130(5):788-797. Hogarty MD, Ziegler DS, Franson A, Chi YY, Tsao-Wei D, Liu K, Vemu R, Gerner EW, Bruckheimer E, Shamirian A, Hasenauer B, Balis FM, Groshen S, Norris MD, Haber M, Park JR, Matthay KK, Marachelian A. PMID: 38200233; PMCID: PMC10912730.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    8. Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111. Kaye EC, Smith J, Zhou Y, Bagatell R, Baker JN, Cohn SL, Diller LR, Glade Bender JL, Granger MM, Marachelian A, Park JR, Rosenberg AR, Shusterman S, Twist CJ, Mack JW. PMID: 38100619; PMCID: PMC10939929.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    9. Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma. Sci Rep. 2023 11 14; 13(1):19915. Lascano D, Zobel MJ, Lee WG, Chen SY, Zamora A, Asuelime GE, Choi SY, Chronopoulos A, Asgharzadeh S, Marachelian A, Park J, Sheard MA, Kim ES. PMID: 37964011; PMCID: PMC10645976.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    10. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I-MIBG in patients with relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30743. Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. PMID: 37885116; PMCID: PMC10842219.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Congenital central hypoventilation syndrome without hypoventilation: is it congenital central hypoventilation syndrome? J Clin Sleep Med. 2023 06 01; 19(6):1161-1164. Wo LL, Itani R, Keens TG, Marachelian A, Ji J, Perez IA. PMID: 36798979; PMCID: PMC10235709.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. Nat Commun. 2023 05 05; 14(1):2601. Berko ER, Witek GM, Matkar S, Petrova ZO, Wu MA, Smith CM, Daniels A, Kalna J, Kennedy A, Gostuski I, Casey C, Krytska K, Gerelus M, Pavlick D, Ghazarian S, Park JR, Marachelian A, Maris JM, Goldsmith KC, Radhakrishnan R, Lemmon MA, Mossé YP. PMID: 37147298; PMCID: PMC10163008.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    13. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 05; 29(5):1092-1102. Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. PMID: 37012551; PMCID: PMC10202811.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    14. Pain mitigation and management strategies for anti-GD2 infusions: An expert consensus. Pediatr Blood Cancer. 2023 05; 70(5):e30217. Nysom K, Morad AG, Rafael MS, Zier J, Marachelian A, Watt T, Morgenstern DA. PMID: 36772891.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    15. Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma. Int J Radiat Oncol Biol Phys. 2023 04 01; 115(5):1115-1128. Campbell K, Groshen S, Evans AC, Wilson S, Sebastian A, Loots GG, Marachelian A, Armant M, Pal S, Haas-Kogan DA, Park JR, Granger M, Matthay KK, Coleman MA, DuBois SG. PMID: 36526235.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    16. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy. Pediatr Blood Cancer. 2022 09; 69(9):e29719. Asgharzadeh S, Marachelian A, Villablanca JG, Liu WY, Kennedy R, Sposto R, Naranjo A, Tenney S, Yu AL, Ozkaynak MF, Sondel PM, Park JR, Seeger RC. PMID: 35441784; PMCID: PMC9329214.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. Radiat Res. 2022 Feb 01; 197(2):101-112. Evans AC, Setzkorn T, Edmondson DA, Segelke H, Wilson PF, Matthay KK, Granger MM, Marachelian A, Haas-Kogan DA, DuBois SG, Coleman MA. PMID: 34673986; PMCID: PMC8870530.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    18. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. PMID: 34270348; PMCID: PMC8547934.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    19. Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: A case series and review of the literature. Pediatr Blood Cancer. 2020 08; 67(8):e28236. Duvalyan A, Cha A, Goodarzian F, Arkader A, Villablanca JG, Marachelian A. PMID: 32386124.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    20. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789. Mack JW, Uno H, Twist CJ, Bagatell R, Rosenberg AR, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park JR, Cohn SL, Fernandez JH, Diller LR, Shusterman S. PMID: 32360991; PMCID: PMC7523916.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    21. The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors. J Surg Res. 2020 05; 249:8-12. Zobel M, Zamora A, Sura A, Wang L, Stein J, Marachelian A, Kim ES. PMID: 31918331.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. Mack JW, Cronin AM, Uno H, Shusterman S, Twist CJ, Bagatell R, Rosenberg A, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park J, Cohn SL, Levine A, Taddei S, Diller LR. PMID: 31584705; PMCID: PMC7523918.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    23. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255. Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. PMID: 31386611; PMCID: PMC6881103.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    24. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149. DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. PMID: 30093449; PMCID: PMC6295246.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    25. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 07; 65(7):e27023. Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR. PMID: 29603591; PMCID: PMC6040651.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    26. Rare MYC-amplified Neuroblastoma With Large Cell Histology. Pediatr Dev Pathol. 2018 Sep-Oct; 21(5):461-466. Matsuno R, Gifford AJ, Fang J, Warren M, Lukeis RE, Trahair T, Sugimoto T, Marachelian A, Asgharzadeh S, Maris JM, Ikegaki N, Shimada H. PMID: 29426276; PMCID: PMC7469889.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 05; 65(5):e26940. Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK. PMID: 29350464; PMCID: PMC7456604.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    28. Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors. Bone Marrow Transplant. 2017 Nov; 52(11):1543-1548. Guerra JA, Dhall G, Marachelian A, Castillo E, Malvar J, Wong K, Sposto R, Finlay JL. PMID: 28783147.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    29. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC. PMID: 28559462.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    30. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. J Pediatr Oncol Nurs. 2017 May/Jun; 34(3):160-172. Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G. PMID: 28061552; PMCID: PMC7523913.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016 10; 66:144-52. Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK. PMID: 27573428; PMCID: PMC7523915.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    32. The clinical management and outcomes of cervical neuroblastic tumors. J Surg Res. 2016 07; 204(1):109-13. Jackson JR, Tran HC, Stein JE, Shimada H, Patel AM, Marachelian A, Kim ES. PMID: 27451875; PMCID: PMC9341276.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. PMID: 27092812; PMCID: PMC8992729.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCellsCTClinical Trials
    34. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. PMID: 26884555; PMCID: PMC4872349.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    35. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, Neville KA, Cohn SL, Bush M, Gunawan R, Lim AP, Smith MA, Smith LM. PMID: 26791869; PMCID: PMC4747995.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    36. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK. PMID: 26506090; PMCID: PMC7523914.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    37. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. PMID: 25695691; PMCID: PMC4470833.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsCTClinical Trials
    38. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. PMID: 25639769.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    39. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31. Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. PMID: 25551355.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    40. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes. 2014 Apr 23; 7:256. Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. PMID: 24755475; PMCID: PMC4006848.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    41. Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors. Pediatr Blood Cancer. 2013 Dec; 60(12):2012-7. Brown RJ, Rahim H, Wong KE, Cooper RM, Marachelian A, Butturini A, Dhall G, Finlay JL. PMID: 23956157.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    42. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. PMID: 23813912; PMCID: PMC4066886.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    43. Forearm skeletal muscle neuroblastoma in a child: a rare primary location. J Pediatr Hematol Oncol. 2013 Jan; 35(1):61-3. Giuliani S, Marachelian A, Franklin A, Shimada H, Grikscheit T. PMID: 23249961.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer. 2012 May; 58(5):675-81. Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG. PMID: 22493777.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    45. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 01; 18(9):2679-86. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. PMID: 22421195; PMCID: PMC6814395.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    46. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. PMID: 21671363; PMCID: PMC3117015.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    47. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL. PMID: 20222020.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    48. Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex. Pediatr Blood Cancer. 2010 Jan; 54(1):170-2. Bavishi S, Wong K, Delgardo T, Marachelian A, Khatua S. PMID: 19760773.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    49. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer. 2009 Jul 01; 115(13):2956-63. Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL. PMID: 19402050.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    50. Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transplant. 2008 Jan; 41(2):167-72. Marachelian A, Butturini A, Finlay J. PMID: 18176620.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    51. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Jul; 45(1):37-42. Jubran RF, Marachelian A, Dorey F, Malogolowkin M. PMID: 15768381.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    52. Impact of human endogenous retroviral elements on cellular genes: strategy for isolation of LTR-driven chimeric transcripts. Leukemia. 1999 Apr; 13 Suppl 1:S97-8. Seifarth W, Krieg-Schneider F, Skladny H, Marachelian A, Germaier H, Hehlmann R, Leib-Mösch C. PMID: 10232379.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    Araz's Networks
    Concepts (220)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (34)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.